Calando Granted Broad Patent Rights to RNAi Technology in China: related news

Calando Granted Broad Patent Rights to RNAi Technology in China

Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today the issuance of Chinese Patent No. 28266625, entitled "Methods and compositions for therapeutic use of RNA interference." The Chinese patent broadly covers all methods of using any RNA interference (‘RNAi') construct formulated "in a supramolecular complex" to attenuate the expression of any target gene. Supramolecular complex formulations are any that are formed with any type of polymer. The patent also broadly covers all pharmaceutical compositions of matter containing RNAi constructs "adapted for pulmonary or nasal delivery" to the lungs.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 10, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

China Kangtai Cactus Biotech Inc. Granted National Invention Patent of China for Use of Cactus to Enhance Immune System

HARBIN, China, May 27 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai Cactus Biotech Inc. (the "Company") (OTC Bulletin Board: CKGT), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based consumer products in China, announced today that its wholly-owned subsidiary Harbin Hainan Kangda Cactus Hygienical Foods Co., Ltd. (the 'Company') has been granted The National Invention Patent of China, a key patent for the nutritional use of cactus to enhance the immune system through its ability to prevent infection and anti-inflammatory diseases. The Company was previously awarded two patents for Cactus Cattle Feed and Cactus Fish Feed by the State Intellectual Property Office and has five patents pending. These include Cactus Poultry Feed, Cactus Pig Feed, Cactus Cattle Feed Additives, Cactus Poultry Feed

International Companies Require China-Specific Patent Strategies

Shanghai, China – May 22, 2008: China, one of the world’s largest and most promising markets, has seen a 20 percent annual increase in patent application filings over the last fifteen years. In 2007, the State Intellectual Property Office (SIPO) of China received 694,153 patent applications, an increase of 21.1 percent over the previous year. These applications included filings for all three types of patents granted in China: Invention patents (valid for 20 years from the date of filing), Utility Models (valid for 10 years), and Design patents (also valid for 10 years). With regard to invention patents (20 year patents), China is currently third in the world behind the United States and Japan. In its latest study, Evalueserve, a global research and analytics firm, forecasts that if patent filings in China continue to grow at the current r

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

Arrowhead Research Subsidiary Granted China RNAi Patent

Calando Pharmaceuticals of Pasadena, CA, received a China patent for broad coverage of all methods of using any RNA interference construct formulated in a supramolecular complex. Supramolecular complex formulations are those formed with any type of polymer. The patent also covers any pharmaceutical compositions of matter containing RNAi constructs adapted for pulmonary or nasal delivery to the lungs.

Composite Technology Announces Issuance of Key Patent

Composite Technology Corporation (CTC) (OTCBB: CPTC) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Composite Technology Announces Issuance of Key Patent

Composite Technology Corporation (CTC) (OTCBB: CPTC) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Composite Technology Announces Issuance of Key Patent

IRVINE, CA--(MARKET WIRE)--May 19, 2008 -- Composite Technology Corporation (CTC) (OTC BB:CPTC.OB - News) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

China In-Focus: China Medicine Retains Australian Patent

July 18, 2008 (FinancialWire) China Medicine Corp. (OTCBB: CHME) (Current Market Cap. US$28.96 Mil.) has obtained a patent from Australia Patent Office for recombinant Aflatoxin Detoxifizyme. The patent is valid through January 13, 2025. According to China Medicine, rADTZ is a product that has the potential to detoxify aflatoxin, a potential cancer causing agent, in food and feed. It is a compound that is a derivation of aflatoxin-detoxifizyme, an extracellular enzyme. Developed by Guangzhou Co-Win Bioengineering Co., Ltd., a subsidiary of China Medicine, rADTZ can be used as an additive to remove aflatoxins from animal feed as well as other food products. The company intends to develop rADTZ for this and other applications. The company is currently testing rADTZ on animal feed and is scheduled to begin working with the Chinese Department

Barr confirms patent challenge of Prevacid SoluTab tablets

Add our medical news to digg - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to NewsVine - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Fark - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Furl - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Shadows - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to YahooMyWeb - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Reddit -Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to StumbleUpon - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Facebook - Barr confirms patent challenge of Prevacid SoluTab tablets

Foreigners may face tighter Chinese patent laws

Foreign companies that make discoveries in China would have to file for a patent in China before anywhere else or risk losing protection of their intellectual property, according to proposed changes to the country's patent law. Another proposal calls for the introduction of an "absolute novelty" standard, which would make it more difficult to obtain a patent in China for inventions already in use overseas. Experts said the changes, which could come into effect this year, would make it easier to challenge rogue Chinese patents, the Financial Times reported. However, the experts also warned that conditions are likely to become more challenging for foreign firms conducting research in China. At present, most of these firms choose to file for patent protection in their home countries, where patent legislation is more mature and robust than in

Barr confirms Entocort patent challenge

Add our medical news to digg - Barr confirms Entocort patent challenge Add our medical news to NewsVine - Barr confirms Entocort patent challenge Add our medical news to Fark - Barr confirms Entocort patent challenge Add our medical news to Furl - Barr confirms Entocort patent challenge Add our medical news to Shadows - Barr confirms Entocort patent challenge Add our medical news to YahooMyWeb - Barr confirms Entocort patent challenge Add our medical news to Reddit -Barr confirms Entocort patent challenge Add our medical news to StumbleUpon - Barr confirms Entocort patent challenge Add our medical news to Facebook - Barr confirms Entocort patent challenge

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Mylan wins generic Prilosec patent litigation

Add our medical news to digg - Mylan wins generic Prilosec patent litigation Add our medical news to NewsVine - Mylan wins generic Prilosec patent litigation Add our medical news to Fark - Mylan wins generic Prilosec patent litigation Add our medical news to Furl - Mylan wins generic Prilosec patent litigation Add our medical news to Shadows - Mylan wins generic Prilosec patent litigation Add our medical news to YahooMyWeb - Mylan wins generic Prilosec patent litigation Add our medical news to Reddit -Mylan wins generic Prilosec patent litigation Add our medical news to StumbleUpon - Mylan wins generic Prilosec patent litigation Add our medical news to Facebook - Mylan wins generic Prilosec patent litigation

Biopure Corporation wins European patent challenge

Add our medical news to digg - Biopure Corporation wins European patent challenge Add our medical news to NewsVine - Biopure Corporation wins European patent challenge Add our medical news to Fark - Biopure Corporation wins European patent challenge Add our medical news to Furl - Biopure Corporation wins European patent challenge Add our medical news to Shadows - Biopure Corporation wins European patent challenge Add our medical news to YahooMyWeb - Biopure Corporation wins European patent challenge Add our medical news to Reddit -Biopure Corporation wins European patent challenge Add our medical news to StumbleUpon - Biopure Corporation wins European patent challenge Add our medical news to Facebook - Biopure Corporation wins European patent challenge

Biopure Wins European Patent Challenge

CAMBRIDGE, Mass., May 19, 2008 /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in France, Germany, the United Kingdom, Ireland, Italy, Spain, and Switzerland. The Opposition Division of the EPO supported Biopure's rights to all of the claims originally granted by the EPO without any modifications or restrictions. The patent challenge was brought in an Opposition by Switzerland-based Octapharma AG.

Biopure Wins European Patent Challenge

CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in France, Germany, the United Kingdom, Ireland, Italy, Spain, and Switzerland. The Opposition Division of the EPO supported Biopure's rights to all of the claims originally granted by the EPO without any modifications or restrictions. The patent challenge was brought in an Opposition by Switzerland-based Octapharma AG.

Search took 0.64 seconds.